Cargando…

A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis

SIMPLE SUMMARY: The use and misuse of antibiotics in the past decades have contributed to the wide spread of antibiotic resistance, which currently represents a major issue and threat to human health. Consequently, the discovery of new anti-infective molecules is of primary importance. In vivo studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Montali, Aurora, Berini, Francesca, Saviane, Alessio, Cappellozza, Silvia, Marinelli, Flavia, Tettamanti, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409246/
https://www.ncbi.nlm.nih.gov/pubmed/36005373
http://dx.doi.org/10.3390/insects13080748
_version_ 1784774804150157312
author Montali, Aurora
Berini, Francesca
Saviane, Alessio
Cappellozza, Silvia
Marinelli, Flavia
Tettamanti, Gianluca
author_facet Montali, Aurora
Berini, Francesca
Saviane, Alessio
Cappellozza, Silvia
Marinelli, Flavia
Tettamanti, Gianluca
author_sort Montali, Aurora
collection PubMed
description SIMPLE SUMMARY: The use and misuse of antibiotics in the past decades have contributed to the wide spread of antibiotic resistance, which currently represents a major issue and threat to human health. Consequently, the discovery of new anti-infective molecules is of primary importance. In vivo studies are crucial for testing the efficacy of novel antibiotics. Invertebrate models look promising to reduce the large-scale use of mammalians, which is mainly limited by high costs and ethical concerns. In this scenario, the silkworm proved to be an interesting alternative among insects. Here, we developed a silkworm infection model by challenging the larvae with Staphylococcus epidermidis, one common cause of infections in hospitals, and assessing the curative effects of three life-saving glycopeptide antibiotics that are used to treat infections caused by multidrug-resistant Gram-positive pathogens. ABSTRACT: The increasing number of microorganisms that are resistant to antibiotics is prompting the development of new antimicrobial compounds and strategies to fight bacterial infections. The use of insects to screen and test new drugs is increasingly considered a promising tool to accelerate the discovery phase and limit the use of mammalians. In this study, we used for the first time the silkworm, Bombyx mori, as an in vivo infection model to test the efficacy of three glycopeptide antibiotics (GPAs), against the nosocomial pathogen Staphylococcus epidermidis. To reproduce the human physiological temperature, the bacterial infection was performed at 37 °C and it was monitored over time by evaluating the survival rate of the larvae, as well the response of immunological markers (i.e., activity of hemocytes, activation of the prophenoloxidase system, and lysozyme activity). All the three GPAs tested (vancomycin, teicoplanin, and dalbavancin) were effective in curing infected larvae, significantly reducing their mortality and blocking the activation of the immune system. These results corroborate the use of this silkworm infection model for the in vivo studies of antimicrobial molecules active against staphylococci.
format Online
Article
Text
id pubmed-9409246
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94092462022-08-26 A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis Montali, Aurora Berini, Francesca Saviane, Alessio Cappellozza, Silvia Marinelli, Flavia Tettamanti, Gianluca Insects Article SIMPLE SUMMARY: The use and misuse of antibiotics in the past decades have contributed to the wide spread of antibiotic resistance, which currently represents a major issue and threat to human health. Consequently, the discovery of new anti-infective molecules is of primary importance. In vivo studies are crucial for testing the efficacy of novel antibiotics. Invertebrate models look promising to reduce the large-scale use of mammalians, which is mainly limited by high costs and ethical concerns. In this scenario, the silkworm proved to be an interesting alternative among insects. Here, we developed a silkworm infection model by challenging the larvae with Staphylococcus epidermidis, one common cause of infections in hospitals, and assessing the curative effects of three life-saving glycopeptide antibiotics that are used to treat infections caused by multidrug-resistant Gram-positive pathogens. ABSTRACT: The increasing number of microorganisms that are resistant to antibiotics is prompting the development of new antimicrobial compounds and strategies to fight bacterial infections. The use of insects to screen and test new drugs is increasingly considered a promising tool to accelerate the discovery phase and limit the use of mammalians. In this study, we used for the first time the silkworm, Bombyx mori, as an in vivo infection model to test the efficacy of three glycopeptide antibiotics (GPAs), against the nosocomial pathogen Staphylococcus epidermidis. To reproduce the human physiological temperature, the bacterial infection was performed at 37 °C and it was monitored over time by evaluating the survival rate of the larvae, as well the response of immunological markers (i.e., activity of hemocytes, activation of the prophenoloxidase system, and lysozyme activity). All the three GPAs tested (vancomycin, teicoplanin, and dalbavancin) were effective in curing infected larvae, significantly reducing their mortality and blocking the activation of the immune system. These results corroborate the use of this silkworm infection model for the in vivo studies of antimicrobial molecules active against staphylococci. MDPI 2022-08-19 /pmc/articles/PMC9409246/ /pubmed/36005373 http://dx.doi.org/10.3390/insects13080748 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Montali, Aurora
Berini, Francesca
Saviane, Alessio
Cappellozza, Silvia
Marinelli, Flavia
Tettamanti, Gianluca
A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
title A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
title_full A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
title_fullStr A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
title_full_unstemmed A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
title_short A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
title_sort bombyx mori infection model for screening antibiotics against staphylococcus epidermidis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409246/
https://www.ncbi.nlm.nih.gov/pubmed/36005373
http://dx.doi.org/10.3390/insects13080748
work_keys_str_mv AT montaliaurora abombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT berinifrancesca abombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT savianealessio abombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT cappellozzasilvia abombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT marinelliflavia abombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT tettamantigianluca abombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT montaliaurora bombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT berinifrancesca bombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT savianealessio bombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT cappellozzasilvia bombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT marinelliflavia bombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis
AT tettamantigianluca bombyxmoriinfectionmodelforscreeningantibioticsagainststaphylococcusepidermidis